Amyris achieves promising in-vivo results for intranasal delivery of rna/nlc vaccine

Emeryville, calif., aug. 20, 2021 /prnewswire/ -- amyris, inc. (nasdaq: amrs), a leading synthetic biotechnology company active in the clean health and beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced promising in-vivo results in a study of its licensed rna vaccine through intranasal delivery, developed in collaboration with the infectious disease research institute (idri).
AMRS Ratings Summary
AMRS Quant Ranking